About: Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 1999 (uk) im März 1999 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en marzu de 1999 (ast) scientific article published on 01 March 1999 (en)
publication date	wds:Q74590600-D409633F-1368-4CC7-A57F-71224C2A004B
publication date	1999-03-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q74590600-086E891D-E7A3-4BA8-859B-774DA12FD782 wds:Q74590600-0E90FD6B-9F31-4405-B0E3-8EB3E77CCF25 wds:Q74590600-1C48857E-0AC0-4AAF-BFE1-7745E43DC00E wds:Q74590600-1C78928B-DB0A-431D-B049-B294A9DF4E48 wds:Q74590600-211D6C9D-E008-468A-9CEA-E6BFC19AA899 wds:Q74590600-302B67FA-70C9-4A3E-A04D-B0FCC7DF0C8F wds:Q74590600-3312044D-3FE0-44D1-9529-9A566256933A wds:Q74590600-4075DFB2-3F50-484A-8D0D-37A50769E5CF wds:Q74590600-42411F4C-3C6D-4E64-9FFA-5878EE7D1EE7 wds:Q74590600-56CED3F3-62A2-4FB5-AF89-BB9A8B9F723F wds:Q74590600-5A686147-692F-46EA-8C05-B53606845AD2 wds:Q74590600-618AEDA6-ED80-4461-AB27-EAEAAA252FD6 wds:Q74590600-6284BC9A-8BFA-4181-B262-316EE8FBD9F4 wds:Q74590600-7C8542A9-2491-4B8B-AC39-51E2404302C8 wds:Q74590600-84B672F5-3008-45CA-BE67-F0D20A296D74 wds:Q74590600-860960AB-A794-48F4-BB45-ADDECFC2E421 wds:Q74590600-86B5F78C-F8D1-4471-B9D6-DE7E9357CE7C wds:Q74590600-924C9563-3957-4E5F-A190-3DF220CCFED0 wds:Q74590600-9851B793-2D37-48F3-A13A-7DBED9E62140 wds:Q74590600-9AAC2D23-496A-4812-8937-239CE925AC59 wds:Q74590600-AD961D44-4EAA-4135-90E1-446FBC521F99 wds:Q74590600-BB63B6EF-0BFB-42BB-9FCF-ABE6CADE9F01 wds:Q74590600-C0D11F2E-35D2-4D50-85E0-87F3B0856313 wds:Q74590600-C55F6EF3-7792-48D4-8D13-FBE79AC7979B wds:Q74590600-C7E5D4E7-D531-48AB-B9A3-EADE19396BD3 wds:Q74590600-C94E1F7C-33EF-4419-8627-66679F0B5A26 wds:Q74590600-CB1BB4FC-E1F6-4AEA-9777-8CC650A7D8F0 wds:Q74590600-CC7FC191-4E9B-4187-8E72-4E40D10F3B69 wds:Q74590600-D48A61D2-2809-4CCD-A69A-6E85131DFBF5 wds:Q74590600-D5FECDCA-9E23-403D-B4A8-6E3B17DF8323 wds:Q74590600-D850180A-5ADD-4CE2-909C-EF6AFE8AF550 wds:Q74590600-DD9554DC-E211-49C8-84E6-3EEC27A487F5 wds:Q74590600-E14CA215-AB3B-40F2-BEB1-B4F1CEE88A9D wds:Q74590600-E3424338-3DE3-46D7-8B82-8B869E85DACB wds:Q74590600-E980077F-4E92-440E-9A9B-2734EB9F2DE8 wds:Q74590600-ED3A6EA6-150D-41E0-8FE8-04566EE0C450 wds:Q74590600-FE9A1937-FAE6-4824-9583-4AF17C05575E wds:Q74590600-FFD0BBA3-94E3-440D-879F-4754D3A0F84B
cites work	Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients Reproducibility and comparison of responses to inhaled histamine and methacholine The use of beta-agonists and the risk of death and near death from asthma Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986 Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma Effect on airway responsiveness of six weeks treatment with salmeterol Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study Regular inhaled beta agonist in asthma: effects on exacerbations and lung function Asthma control during and after cessation of regular beta 2-agonist treatment Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma Regular vs as-needed inhaled salbutamol in asthma control Beta-adrenergic bronchodilators Bronchial reactivity to inhaled histamine: a method and clinical survey Regular inhaled beta-agonist treatment in bronchial asthma. Regular inhaled salbutamol and airway responsiveness to allergen Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma Rapid onset of tolerance to the bronchoprotective effect of salmeterol Guidelines for the management of asthma: a summary. British Thoracic Society and others Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. Determination of histamine PC20. Comparison of linear and logarithmic interpolation. Salmeterol tachyphylaxis in steroid treated asthmatic subjects Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol Asthma and the beta agonist debate The beta-agonist dilemma Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (2). Why beta-agonists should not be used regularly Is the routine use of inhaled beta-adrenergic agonists appropriate in asthma treatment? No Inhaled beta 2-agonists in the treatment of asthma. Use of beta 2 agonists in asthma: much ado about nothing? Still cause for concern Controversies in respiratory medicine: regular inhaled beta-agonists--clear clinical benefit or a hazard to health? (1). Beta-agonists can be used safely and beneficially in asthma
author name string	wds:Q74590600-27B97D1D-AD2B-4E40-9BA6-36596EF6A76A wds:Q74590600-4FBB81EC-42CA-4F9E-A207-59DD2F41F0A7 wds:Q74590600-5F8826B3-97A3-43BC-9508-D3CB78813C5F wds:Q74590600-6CC567C9-57C9-4059-855B-749E559752CE wds:Q74590600-8F398442-CB04-417A-9CA8-5B2580030953 wds:Q74590600-CA7714B8-81CC-423D-A2A6-90D977A964E1 wds:Q74590600-E5A66BBD-0B4B-4B04-A0D0-ED1772E19FEC
author name string	J M FitzGerald K R Chapman R Brambilla G Della Cioppa D Stubbing M S Fairbarn M D Till
rdfs:label	Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group (en) Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software